Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Cash & Equivalents (2016 - 2025)

Acro Biomedical (ACBM) has 10 years of Cash & Equivalents data on record, last reported at $4098.0 in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 760.92% year-over-year to $4098.0; the TTM value through Dec 2025 reached $4098.0, up 760.92%, while the annual FY2025 figure was $4098.0, 760.92% up from the prior year.
  • Cash & Equivalents reached $4098.0 in Q4 2025 per ACBM's latest filing, down from $4323.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $357668.0 in Q1 2022 and bottomed at $26.0 in Q2 2025.
  • Average Cash & Equivalents over 5 years is $44959.0, with a median of $3684.5 recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 99042.95% in 2021, then plummeted 99.91% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $95248.0 in 2021, then plummeted by 93.86% to $5852.0 in 2022, then plummeted by 93.57% to $376.0 in 2023, then increased by 26.6% to $476.0 in 2024, then surged by 760.92% to $4098.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $4098.0 in Q4 2025, $4323.0 in Q3 2025, and $26.0 in Q2 2025.